Issued 2026-09-16 at $12.14 · now $12.14 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, AMCX has typically landed between $9.15 and $15.21 — a range of −24.6% to +25.3% from the issuance price $12.14.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
3,814 overlapping 1 month windows · 2011-06-16 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($12.14) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where AMCX has typically landed a month from the 2026-09-16 close of $12.14 — the range is history, not a prediction.
- now $12.14 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $12.01 (-1.1%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $10.73–$13.3
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $9.15–$15.21
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-06-03 | −47.4% | −49.9% | +0.0% |
| 2024-05-28 | −46.2% | −46.2% | +7.4% |
| 2024-06-04 | −46.0% | −49.0% | +0.0% |
| 3 best | |||
| 2020-12-23 | +77.3% | −2.4% | +77.3% |
| 2020-12-22 | +72.7% | +0.0% | +72.7% |
| 2021-02-04 | +66.0% | +0.0% | +66.0% |
3,814 overlapping windows · 2011-06-16 – 2026-09-16 · not cherry-picked
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~16 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 | Sherin Michael J. III | officer | Sale | 10,648 @ $12.35 | $132K | −100.0% of holding | not yet — horizon still open | not yet — horizon still open | 0 | Form 4 · filed 2 days after the trade |
| 2026-03-10 | Sherin Michael J. III | officer | Sale | 2,700 @ $7.95 | $21K | −16.3% of holding | −6.2% | +32.0% | 13,911 | Form 4 · filed 1 day after the trade |
| 2026-03-10 | Sherin Michael J. III | officer | Sale | 2,400 @ $7.97 | $19K | −18.4% of holding | −6.2% | +32.0% | 10,648 | Form 4 · filed 1 day after the trade |
| 2026-03-10 | Sherin Michael J. III | officer | Sale | 863 @ $7.97 | $7K | −6.2% of holding | −6.2% | +32.0% | 13,048 | Form 4 · filed 1 day after the trade |
| 2025-03-11 | Charles F. Dolan 2009 Revocable Trust | other | Sale | 20,833 @ $6.89 | $144K | −100.0% of holding | −11.4% | −10.0% | 0 | Form 4 · filed 1 day after the trade |
| 2025-03-10 | Charles F. Dolan 2009 Revocable Trust | other | Sale | 154,345 @ $6.95 | $1.1M | −88.1% of holding | −9.0% | −5.2% | 20,833 | Form 4 · filed 2 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
292 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-15 | Cohen Joseph | director | Option exercise | 40,206 | 40,206 | Form 4 |
| 2026-09-15 | Cohen Joseph | director | Disposition | 40,206 | 0 | Form 4 |
| 2026-09-15 | Mills Stephen | director | Option exercise | 29,236 | 29,736 | Form 4 |
| 2026-09-15 | Mills Stephen | director | Disposition | 29,236 | 500 | Form 4 |
| 2026-09-15 | Cohen Joseph | director | Option exercise | 40,206 | 3,647 | Form 4 |
| 2026-09-15 | Mills Stephen | director | Option exercise | 29,236 | 0 | Form 4 |
| 2026-09-15 | Cohen Joseph | director | Option exercise | 40,206 | 3,647 | Form 4 |
| 2026-09-15 | Mills Stephen | director | Option exercise | 29,236 | 0 | Form 4 |
| 2026-06-16 | Lokhandwala Hozefa | officer | Award / grant | 19,511 | 19,511 | Form 4 |
| 2026-06-16 | Lokhandwala Hozefa | officer | Award / grant | 19,511 | 19,511 | Form 4 |
| 2026-06-16 | Blank Matthew | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | DOLAN JAMES LAWRENCE | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Cox Christopher James | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Perelman Debra Golding | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | TESE VINCENT | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | VOGEL CARL E | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Perelman Debra Golding | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | TESE VINCENT | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | VOGEL CARL E | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Cox Christopher James | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Lokhandwala Hozefa | officer | Award / grant | 19,511 | 19,511 | Form 4 |
| 2026-06-16 | Lokhandwala Hozefa | officer | Award / grant | 19,511 | 19,511 | Form 4 |
| 2026-06-16 | Blank Matthew | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Sweeney Brian | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Dolan Aidan J | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Sweeney Brian | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | DOLAN THOMAS CHARLES | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Dolan Aidan J | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | Sweeney Brian | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | DOLAN THOMAS CHARLES | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | DOLAN JAMES LAWRENCE | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-06-16 | DOLAN JAMES LAWRENCE | director | Award / grant | 10,926 | 10,926 | Form 4 |
| 2026-03-11 | Dolan Kristin A | director | Award / grant | 503,778 | 503,778 | Form 4 |
| 2026-03-11 | Kelleher Kimberly | officer | Award / grant | 88,161 | 88,161 | Form 4 |
| 2026-03-11 | McDermott Dan | officer | Award / grant | 100,756 | 100,756 | Form 4 |
| 2026-03-11 | Romanello Salvatore | officer | Award / grant | 50,378 | 50,378 | Form 4 |
| 2026-03-11 | McDermott Dan | officer | Award / grant | 100,756 | 100,756 | Form 4 |
| 2026-03-11 | Romanello Salvatore | officer | Award / grant | 50,378 | 50,378 | Form 4 |
| 2026-03-11 | Sherin Michael J. III | officer | Award / grant | 21,411 | 21,411 | Form 4 |
| 2026-03-11 | Dolan Kristin A | director | Award / grant | 503,778 | 503,778 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.